Why Are GLP-1 Medications So Expensive in the US?

The Sticker Price: What GLP-1s Actually Cost Americans

A single month of brand-name semaglutide (Wegovy) carries a wholesale acquisition cost (WAC) near $1,349, while tirzepatide (Zepbound) lists at approximately $1,059 per month at the highest maintenance dose [1]. These figures place GLP-1 receptor agonists among the most expensive chronic-use medications in the US formulary. For patients without insurance coverage or those facing high-deductible plans, the annual out-of-pocket burden can exceed $16,000.

This is not a global phenomenon. A 2024 RAND Corporation analysis found that US prescription drug prices, on average, are 2.78 times higher than prices in 33 other OECD countries [2]. GLP-1s follow this pattern to an extreme degree. Ozempic (semaglutide 1 mg for type 2 diabetes) costs roughly $936 per month in the US, while the same product retails for approximately $155 in Canada and $59 in Germany [3]. The price gap is not explained by manufacturing costs. Novo Nordisk has stated that the cost of goods for semaglutide is a small fraction of the list price, with the majority of revenue directed toward R&D reinvestment, rebates, and commercial operations.

Patients notice. A 2023 KFF Health Tracking Poll found that 82% of US adults described the cost of prescription drugs as "unreasonable," and GLP-1 medications ranked among the most frequently cited examples of unaffordable therapies [4].

Patent Monopolies and the Absence of Generic Competition

US patent law grants brand-name drugmakers extended periods of market exclusivity, and GLP-1 manufacturers have layered multiple patents to maximize that window. Novo Nordisk holds dozens of patents related to semaglutide, covering the molecule itself, the delivery device, specific dosing regimens, and manufacturing processes. Key formulation patents do not expire until 2031-2032 [5].

Without generic or biosimilar alternatives available, there is no price competition. This is the single largest structural driver of high GLP-1 costs.

The FDA approved the first biosimilar GLP-1 product in late 2025, but broad market availability is still projected to lag by 12-18 months due to manufacturing scale-up and patent litigation. Eli Lilly's tirzepatide (Mounjaro, Zepbound) faces a similar patent field, with exclusivity extending into the early 2030s. Until multiple biosimilar entrants reach pharmacies, the duopoly between Novo Nordisk and Eli Lilly means neither company faces meaningful pricing pressure from competitors.

Dr. Aaron Kesselheim, professor of medicine at Harvard Medical School and a researcher on pharmaceutical policy, has noted: "The US patent system allows companies to build 'patent thickets' around biologics like GLP-1 agonists, effectively extending monopoly pricing well beyond the original 20-year patent term" [6].

The PBM Rebate System: How Middlemen Inflate List Prices

Pharmacy benefit managers (PBMs) negotiate drug prices between manufacturers and health plans. In theory, PBMs reduce costs. In practice, the rebate structure creates a perverse incentive for higher list prices. Manufacturers set a high WAC, then offer rebates of 40-60% to PBMs in exchange for preferred formulary placement. The PBM retains a portion of that rebate as profit.

Novo Nordisk disclosed in its 2024 annual report that approximately 51% of its US gross revenue was paid out in rebates, discounts, and fees to supply chain intermediaries [7]. This means the company's net price per Wegovy prescription is roughly half the list price. The patient paying cash at the pharmacy counter, however, sees the full WAC.

The three largest PBMs (CVS Caremark, Express Scripts, and OptumRx) control roughly 80% of US prescription claims. Their consolidated market power means they can demand large rebates from manufacturers, but those savings do not always reach the patient in the form of lower copays. A 2024 Federal Trade Commission interim report on PBM practices found that PBM markups and fee structures often increased patient out-of-pocket costs for brand-name drugs, even when the PBM had negotiated a substantial rebate [8].

This is particularly damaging for GLP-1 patients on high-deductible health plans. Until the deductible is met, the patient pays based on the list price, not the net price the insurer actually pays.

No Government Price Negotiation (Until Recently)

The US is the only major high-income country where the government historically did not negotiate drug prices for its largest public insurance program. Medicare Part D, which covers outpatient prescription drugs for over 50 million Americans, was explicitly prohibited from negotiating prices directly with manufacturers under the 2003 Medicare Modernization Act.

The Inflation Reduction Act (IRA) of 2022 changed this for a limited set of drugs. Medicare can now negotiate prices for select high-spend medications, with the first negotiated prices taking effect in 2026 [9]. Semaglutide and tirzepatide are strong candidates for future negotiation rounds, given their combined Medicare spending, which exceeded $10 billion in 2024 alone.

The Congressional Budget Office (CBO) projected that IRA drug price negotiations will save Medicare approximately $98.5 billion over a decade, but those savings will phase in slowly and initially cover only 10 drugs per year, increasing to 20 by 2029 [10].

Meanwhile, coverage for GLP-1 medications under Medicare Part D remains largely restricted to patients with a type 2 diabetes diagnosis. Medicare does not cover anti-obesity medications, which means Wegovy and Zepbound are not reimbursed for their weight-management indications in most Part D plans. Bipartisan legislation (the Treat and Reduce Obesity Act) has been introduced in multiple Congressional sessions to change this, but it has not passed as of mid-2026.

Direct-to-Consumer Advertising Drives Demand and Supports Premium Pricing

The US is one of only two countries (along with New Zealand) that permits direct-to-consumer (DTC) pharmaceutical advertising on television. Novo Nordisk spent approximately $447 million on DTC advertising for Ozempic and Wegovy in 2023, making semaglutide one of the most heavily advertised drugs in the country [11].

DTC advertising works. It drives patient demand, which in turn gives manufacturers pricing power. When patients request a specific branded drug by name, physicians are more likely to prescribe it, and insurers face pressure to cover it. This demand loop supports premium pricing because the manufacturer can maintain high list prices while absorbing advertising costs as a fraction of total revenue.

Novo Nordisk's total 2024 revenue from semaglutide products exceeded $28 billion globally, with the US accounting for approximately 60% of that figure [7]. At those revenue levels, even $500 million in annual advertising spend represents less than 3% of semaglutide revenue.

The R&D Cost Argument: Legitimate but Overstated

Pharmaceutical manufacturers argue that high drug prices reflect the cost of research and development. Drug development is expensive. A 2020 analysis in JAMA estimated the median capitalized R&D cost per new drug at $985 million, though estimates vary widely depending on methodology [12].

GLP-1 receptor agonists required genuine scientific innovation. Semaglutide was the product of decades of incremental research on incretin biology, beginning with the discovery of GLP-1 in the 1980s and progressing through multiple clinical programs. The STEP trial program alone (STEP 1 through STEP 5) enrolled over 5,000 participants across multiple countries to establish semaglutide 2.4 mg as an effective weight-management therapy [13].

The R&D argument has limits, though. Novo Nordisk's R&D expenditure in 2024 was approximately $6.2 billion, while its net profit exceeded $13 billion [7]. The company's profit margin on semaglutide products is estimated at 80-90% after cost of goods. R&D costs are real, but they do not explain why the same molecule is priced 5-10 times higher in the US than in countries where manufacturers still earn a profit.

Dr. Peter Bach, former director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering, has stated: "Companies price drugs in the US at whatever the market will bear. The R&D cost story is a justification constructed after the pricing decision, not a formula that determines it" [14].

Insurance Coverage Gaps Leave Millions Paying Full Price

Even with insurance, GLP-1 coverage is inconsistent. A 2024 analysis by the Employers' Health Coalition found that only 49% of large employer-sponsored plans covered GLP-1 medications for weight management, and many of those plans imposed prior authorization requirements, step therapy protocols, or annual coverage caps [15].

Barriers to coverage include:

• Prior authorization: most plans require documented BMI thresholds (typically BMI ≥30, or ≥27 with a comorbidity), plus evidence of failed lifestyle interventions
• Step therapy: some insurers require patients to try older, less effective weight-loss medications (phentermine, orlistat) before approving a GLP-1
• Duration limits: certain plans cap GLP-1 coverage at 12-24 months, despite clinical evidence that weight regain occurs rapidly after discontinuation [16]
• Formulary exclusions: plans may cover Ozempic (diabetes indication) but explicitly exclude Wegovy (obesity indication), even though both contain semaglutide

For the uninsured or underinsured, manufacturer savings programs offer partial relief. Novo Nordisk's Wegovy savings card can reduce out-of-pocket costs to as low as $0-$25 per month for commercially insured patients, but these programs typically exclude Medicare, Medicaid, and Tricare beneficiaries.

How US GLP-1 Pricing Compares Internationally

International reference pricing makes the US outlier status unmistakable. The following comparisons use approximate monthly costs at standard maintenance doses:

Semaglutide 2.4 mg (Wegovy) costs approximately $1 to 349 in the US, $295 in the UK, $210 in Germany, and $150 in Japan [3]. The price differences exist because other countries use health technology assessment (HTA) bodies to evaluate cost-effectiveness and negotiate maximum reimbursement prices. The UK's National Institute for Health and Care Excellence (NICE), for example, evaluates drugs against a cost-per-quality-adjusted-life-year (QALY) threshold and will not recommend NHS funding for products that exceed roughly £20,000-£30,000 per QALY gained [17].

The US has no equivalent federal HTA body for private insurance pricing. Medicare's new negotiation authority under the IRA represents a partial step in this direction, but it applies only to Medicare, not to the commercial market.

What May Bring Prices Down

Several forces are converging that could reduce GLP-1 costs over the next 3-5 years.

Biosimilar entry. The FDA pathway for biosimilar peptides is established, and multiple manufacturers have filed abbreviated new drug applications for semaglutide biosimilars. Analysts project the first interchangeable semaglutide biosimilar could reach US pharmacies by 2032-2033, with earlier entry possible if patent challenges succeed [5].

IRA price negotiation. If semaglutide or tirzepatide is selected for Medicare price negotiation in a future cycle, the negotiated price (capped at a percentage of the non-federal average manufacturer price) could set a benchmark that influences commercial pricing.

Compounding pharmacies. During FDA-declared drug shortages, compounding pharmacies have been permitted to produce semaglutide and tirzepatide at significantly lower costs (typically $150-$400 per month). The legal status of compounded GLP-1s remains contested, and the FDA has taken enforcement actions against some compounders, but demand has been substantial [18].

Employer and insurer pushback. As GLP-1 spending consumes a growing share of pharmacy budgets, large employers and insurers are negotiating more aggressively with manufacturers and PBMs. Some employers have contracted directly with manufacturers, bypassing PBMs entirely, to secure lower net prices.

State-level legislation. Several US states have introduced bills requiring PBM transparency, mandating that rebates be passed through to patients at the point of sale, or capping insulin-style copays for GLP-1 medications. None have passed into law for GLP-1s specifically as of mid-2026, but the legislative momentum is growing.

What Patients Can Do Right Now

Patients facing high GLP-1 costs have several options worth exploring with their prescribing clinician.

First, check manufacturer savings programs. Novo Nordisk and Eli Lilly both offer savings cards that can reduce monthly costs to $0-$25 for eligible commercially insured patients. Eligibility requirements and benefit caps change frequently, so verify current terms directly.

Second, ask about formulary alternatives. If your plan covers Mounjaro but not Zepbound (or vice versa), your clinician may be able to prescribe the covered product for an appropriate indication. Tirzepatide and semaglutide have comparable efficacy in head-to-head data from the SURMOUNT and STEP programs [19].

Third, appeal prior authorization denials. Plans deny GLP-1 coverage at high rates initially, but appeal success rates are meaningful. Provide complete documentation of BMI history, comorbidities (type 2 diabetes, obstructive sleep apnea, cardiovascular disease), and prior treatment attempts.

Fourth, ask about patient assistance programs. Both Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares) offer free or reduced-cost medication to qualifying uninsured patients with household incomes below 400% of the federal poverty level.

The average monthly out-of-pocket cost for a commercially insured patient using a manufacturer savings card is approximately $25-$50, compared to $900+ without one [1].